Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation
The causation theory is supported by scientific studies indicating that PPS accumulates in the retinal pigment epithelium (RPE), leading to cellular toxicity and pigmentary maculopathy. Peer-reviewed research, including a 2021 study in JAMA Ophthalmology, demonstrates a strong correlation between long-term PPS use and retinal changes. The FDA issued warnings in 2020 about retinal pigmentary changes associated with PPS, emphasizing the risk of irreversible vision impairment. Expert opinions and legal case reports further confirm the causal relationship, with PPS's affinity for glycosaminoglycans in the RPE causing cellular toxicity and subsequent retinal degeneration.
286
Pending actions
1,988
Total actions filed
Active
Status
12/15/2020
Established
Who qualifies
Plaintiffs must have used Elmiron (Pentosan Polysulfate Sodium) for a minimum of 6 months to several years, at standard therapeutic dosages (typically 100 mg daily), with injuries diagnosed via ophthalmological examination, including OCT imaging confirming pigmentary maculopathy or retinal changes. Medical records and prescription proof are required, and injuries must be causally linked to Elmiron, supported by expert medical opinion. Plaintiffs are also required to submit a detailed Plaintiff Fact Sheet within specified timeframes.
Products involved
- Elmiron (Pentosan Polysulfate Sodium)
Alleged injuries
- Maculopathy
- Retinal damage
- Vision loss
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
